NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Kamada's 2026 Growth Targets and Business Strategy FAQ
TL;DR
Kamada Ltd. offers investors a competitive edge with projected 13% revenue and 23% EBITDA growth in 2026, driven by proprietary plasma therapies and market expansion.
Kamada's growth stems from organic expansion of its plasma-derived therapeutics and distribution segments, plus plasma collection from three Texas centers, reducing third-party dependency.
Kamada's plasma-derived therapies and global distribution improve patient access to critical treatments in over 30 countries, advancing healthcare worldwide.
Kamada's Texas plasma centers can collect 50,000 liters annually each, generating up to $10 million revenue at full capacity while supplying industry peers.
Found this article helpful?
Share it with your network and spread the knowledge!
Kamada expects 2026 revenue of $200-205 million (13% year-over-year growth) and adjusted EBITDA of $50-53 million (23% year-over-year growth), with all growth being organic.
Growth is driven by Kamada's specialty plasma-derived therapeutics business (including products like KAMRAB®, GLASSIA®, HEPAGAM®, and VARIZIG®), its distribution segment expansion, and plasma collection from its Texas centers.
Kamada markets its products in over 30 countries, with specific growth expected in the U.S. market for plasma-derived therapeutics and expansion of its distribution business to the Middle East and North Africa (MENA) region, including Israel.
Kamada operates three plasma collection centers in Texas (Houston and San Antonio) with annual capacity of approximately 50,000 liters each, contributing an estimated $8-10 million in annual revenue per site at full capacity while reducing dependency on third-party suppliers.
Kamada is receiving reduced GLASSIA royalty payments from Takeda Pharmaceutical in 2026 (the first full year with a lower rate), but the company considers achieving profitable growth despite this reduction as a testament to its strength.
Beyond organic growth, Kamada is focused on new business development deals and acquisitions to enrich its current portfolio of marketed products and generate synergies with existing commercial operations.
Kamada expects to end 2025 with about $75 million in cash and is entering 2026 from a position of significant commercial and financial strength, with consistent conversion of adjusted EBITDA into operational cash.
Kamada intends to publish its 2025 financial results during the first half of March.
Amir London, Kamada's Chief Executive Officer, stated the company enters 2026 from a position of significant commercial and financial strength and is excited about progress made over the past year.
For more information about how Kamada is capitalizing on market opportunities, you can visit their website at https://www.kamada.com/.
Curated from NewMediaWire
